In case you missed it, our CEO, Jacob Rubens, spoke on one of Flagship Pioneering's panels at the 2025 J.P. Morgan Healthcare Conference about the power of platform technologies. Tune in as he discusses the development of our #SomaticGenomics platform & its potential impact on #DrugDiscovery and development: https://bit.ly/3WvxQjA
关于我们
Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com
- 网站
-
https://quotient-tx.com/
Quotient Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
Quotient Therapeutics员工
动态
-
This International Day of #WomenAndGirlsInScience, we're celebrating the incredible women on our team whose passion and expertise drive innovation and inspire us daily as we pioneer the field of #SomaticGenomics. #WomenInSTEM
-
At Quotient, we are unlocking the potential of #SomaticGenomics. In the latest edition from MedNous, our CEO, Jacob Rubens, shares how advancements in somatic genomic analysis are redefining our understanding of biology and driving the development of innovative therapeutics. Read the full article: https://bit.ly/4hH793x
-
-
From Watson and Crick’s discovery of the double helix to the Human Genome Project, American and British teams have a long and successful track record of shaping the future of biology. In this article from The Economist, correspondent Georgia Banjo puts Quotient next on this list. With cutting-edge #SomaticGenomics research in the UK and biotech development expertise in the US, we are unlocking the next great genetics transformation in medicine. Read the full article here: https://bit.ly/4aIeKfU
-
-
In case you missed it, our Head of Platform, Simon Brunner, was featured in the latest Scrip Asks issue discussing the role that AI and #SomaticGenomics play to uncover novel drug targets informed by the true complexity of human biology. Read more here: https://bit.ly/3PWQjBR
-
-
From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFounded companies advancing novel science and platforms to make #BiggerLeaps for human health. Watch all the conversations: https://lnkd.in/eXA6nUcD ? ? ?? Lovisa Afzelius, Co-founder & CEO, Prologue Medicines? ?? Brian Alexander, CEO, Valo Health ?? Stéphane Bancel, CEO, Moderna? ?? Jason Gardner, CEO, Ampersand Biomedicines? ?? Margo Georgiadis, Co-founder & CEO, Montai Therapeutics ? ?? Adrian Gottschalk, CEO, Foghorn Therapeutics Inc.? ?? Steve Hahn, CEO, Harbinger Health? ?? Steve Harr, CEO, Sana Biotechnology, Inc. ? ?? Angela Hwang, CEO, Metaphore Biotechnologies? ?? John Lepore, MD, CEO, ProFound Therapeutics ? ?? Michael Nally, CEO, Generate:Biomedicines? ?? Jason Park, Co-founder & CEO, Empress Therapeutics?? ?? Guillaume Pfefer, CEO, Sail Biomedicines ? ?? Jacob Rubens, CEO, Quotient Therapeutics ? ?? Michael Severino, CEO, Tessera Therapeutics? ?? Eric Shaff, CEO, Seres Therapeutics ?? Torben Straight Nissen, CEO, Repertoire Immune Medicines? ???Jens H. Vogel, Ph.D., President & COO, Mirai Bio ? ?? Michelle Werner, CEO, Alltrna ? ?? Craig Williams, CEO, Apriori Bio? ? #JPM25 #FlagshipStudio?
-
Our CEO, Jacob Rubens, visited the Flagship Pioneering Studio at this year's J.P. Morgan conference to discuss how Quotient is using #SomaticGenomics to transform drug discovery and development, as well as highlight some recent progress from the company. Watch the full video here: https://bit.ly/42hKIxp #FlagshipJPM #JPM25
-
Polyintelligence: the fusion of human, machine, and nature’s intelligence.? ? In Flagship Pioneering’s annual letter, Founder & CEO Noubar Afeyan reflects on polyintelligence and its transformative potential in science and technology. Learn more about how we’re applying polyintelligence at Quotient, featuring a case study on how we are pioneering the new frontier of human genetics: https://lnkd.in/eUGvJ9SQ #FlagshipFounded
Read or?listen to Flagship?Pioneering’s 2025 Annual Letter in which?Founder & CEO Noubar Afeyan?explores polyintelligence?— the?synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology:?bit.ly/Polyintelligence ? Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond. ? And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section:?bit.ly/FlagshipPolyintell ? #BiggerLeaps #FlagshipStudio #JPM25
-
As we reflect on 2024, we’re proud of the strides we’ve made - from expanding our team, to advancing our #SomaticGenomics platform, and announcing two research programs in partnership with Pfizer. We look forward to continued growth in 2025.
-
-
Our genomes are more dynamic and complex than we once thought. In his recent piece in The Atlantic, Jason Liebowitz explores the power of #SomaticMutations, a hidden factor behind some conditions like cancer, heart disease and more. He includes insights from our CEO, Jacob Rubens on the immense genomic variation within each of our cells. Read the full article here: https://bit.ly/4j0RXQf
Doctors Thought They Knew What a Genetic Disease Is. They Were Wrong.
theatlantic.com